Bristol Myers lines up Opdivo treatment in Pakistan, Rwanda and beyond as part of 10-year access campaign

When it comes to supporting cancer care and other therapeutic approaches in low- and middle-income countries (LMICs), Bristol Myers Squibb is taking a long-term view.

In its quest to reach more than 200,000 patients with its medicines in LMICs by 2033, BMS on Wednesday said it's embarking on a new 10-year effort to bolster access.